CA2466808C - Formulations for use in medical or diagnostic procedures - Google Patents
Formulations for use in medical or diagnostic procedures Download PDFInfo
- Publication number
- CA2466808C CA2466808C CA002466808A CA2466808A CA2466808C CA 2466808 C CA2466808 C CA 2466808C CA 002466808 A CA002466808 A CA 002466808A CA 2466808 A CA2466808 A CA 2466808A CA 2466808 C CA2466808 C CA 2466808C
- Authority
- CA
- Canada
- Prior art keywords
- formulation
- diagnostic
- imaging
- weight
- diagnostic procedure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 111
- 238000009472 formulation Methods 0.000 title claims abstract description 109
- 238000002405 diagnostic procedure Methods 0.000 title claims abstract description 43
- 229920000161 Locust bean gum Polymers 0.000 claims abstract description 76
- 235000010420 locust bean gum Nutrition 0.000 claims abstract description 76
- 239000000711 locust bean gum Substances 0.000 claims abstract description 76
- 238000000034 method Methods 0.000 claims abstract description 68
- 239000000594 mannitol Substances 0.000 claims abstract description 67
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 65
- 229930195725 Mannitol Natural products 0.000 claims abstract description 64
- 235000010355 mannitol Nutrition 0.000 claims abstract description 64
- 239000003381 stabilizer Substances 0.000 claims abstract description 40
- 239000002357 osmotic agent Substances 0.000 claims abstract description 36
- 238000002059 diagnostic imaging Methods 0.000 claims abstract description 28
- 150000001875 compounds Chemical class 0.000 claims abstract description 13
- 239000000416 hydrocolloid Substances 0.000 claims abstract description 11
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 5
- 238000003384 imaging method Methods 0.000 claims description 50
- 239000007864 aqueous solution Substances 0.000 claims description 31
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 21
- 239000012530 fluid Substances 0.000 claims description 21
- 239000000126 substance Substances 0.000 claims description 19
- 238000012636 positron electron tomography Methods 0.000 claims description 16
- 210000000813 small intestine Anatomy 0.000 claims description 16
- 238000002627 tracheal intubation Methods 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 208000025865 Ulcer Diseases 0.000 claims description 9
- 210000002784 stomach Anatomy 0.000 claims description 9
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 8
- 230000030136 gastric emptying Effects 0.000 claims description 8
- 208000011231 Crohn disease Diseases 0.000 claims description 7
- 210000003405 ileum Anatomy 0.000 claims description 7
- 210000001630 jejunum Anatomy 0.000 claims description 7
- 230000003902 lesion Effects 0.000 claims description 7
- 210000001165 lymph node Anatomy 0.000 claims description 7
- 210000000496 pancreas Anatomy 0.000 claims description 7
- 210000005166 vasculature Anatomy 0.000 claims description 7
- 210000001072 colon Anatomy 0.000 claims description 6
- 210000004185 liver Anatomy 0.000 claims description 6
- 210000000952 spleen Anatomy 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
- 206010000269 abscess Diseases 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 5
- 238000001574 biopsy Methods 0.000 claims description 5
- 150000004676 glycans Chemical class 0.000 claims description 5
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- 230000001174 ascending effect Effects 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 229960003276 erythromycin Drugs 0.000 claims description 4
- 210000000232 gallbladder Anatomy 0.000 claims description 4
- 210000002429 large intestine Anatomy 0.000 claims description 4
- 230000036269 ulceration Effects 0.000 claims description 4
- 210000004534 cecum Anatomy 0.000 claims description 3
- 210000001198 duodenum Anatomy 0.000 claims description 3
- 210000000664 rectum Anatomy 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 238000012546 transfer Methods 0.000 claims description 3
- 208000032843 Hemorrhage Diseases 0.000 claims description 2
- 238000012879 PET imaging Methods 0.000 claims description 2
- 208000034158 bleeding Diseases 0.000 claims description 2
- 230000000740 bleeding effect Effects 0.000 claims description 2
- 150000002016 disaccharides Chemical class 0.000 claims description 2
- 208000007784 diverticulitis Diseases 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- KJBLQGHJOCAOJP-UHFFFAOYSA-N metoclopramide hydrochloride Chemical compound O.Cl.CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC KJBLQGHJOCAOJP-UHFFFAOYSA-N 0.000 claims description 2
- 150000002772 monosaccharides Chemical class 0.000 claims description 2
- 239000000952 serotonin receptor agonist Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 10
- 238000004519 manufacturing process Methods 0.000 claims 9
- 210000001124 body fluid Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 238000012831 peritoneal equilibrium test Methods 0.000 claims 1
- 238000012877 positron emission topography Methods 0.000 claims 1
- 238000002603 single-photon emission computed tomography Methods 0.000 claims 1
- 238000002595 magnetic resonance imaging Methods 0.000 abstract description 28
- 238000003325 tomography Methods 0.000 abstract description 4
- 239000002872 contrast media Substances 0.000 description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 38
- 239000000243 solution Substances 0.000 description 31
- 238000002600 positron emission tomography Methods 0.000 description 25
- 238000002591 computed tomography Methods 0.000 description 24
- 230000000694 effects Effects 0.000 description 14
- 229910052788 barium Inorganic materials 0.000 description 12
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 12
- 230000037406 food intake Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 229940042003 metamucil Drugs 0.000 description 10
- 238000005259 measurement Methods 0.000 description 9
- 206010012735 Diarrhoea Diseases 0.000 description 8
- 229940039231 contrast media Drugs 0.000 description 8
- 239000000700 radioactive tracer Substances 0.000 description 8
- 239000000654 additive Substances 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 206010000060 Abdominal distension Diseases 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 231100000397 ulcer Toxicity 0.000 description 5
- 206010028813 Nausea Diseases 0.000 description 4
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 210000003384 transverse colon Anatomy 0.000 description 4
- GZCGUPFRVQAUEE-UHFFFAOYSA-N 2,3,4,5,6-pentahydroxyhexanal Chemical compound OCC(O)C(O)C(O)C(O)C=O GZCGUPFRVQAUEE-UHFFFAOYSA-N 0.000 description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000013170 computed tomography imaging Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 206010061424 Anal cancer Diseases 0.000 description 2
- 208000007860 Anus Neoplasms Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 2
- 240000008886 Ceratonia siliqua Species 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- -1 Metamucil Substances 0.000 description 2
- 235000000380 Nyssa aquatica Nutrition 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- WQZGKKKJIJFFOK-UHFFFAOYSA-N alpha-D-glucopyranose Natural products OCC1OC(O)C(O)C(O)C1O WQZGKKKJIJFFOK-UHFFFAOYSA-N 0.000 description 2
- 201000011165 anus cancer Diseases 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 210000001731 descending colon Anatomy 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000003736 gastrointestinal content Anatomy 0.000 description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000012634 optical imaging Methods 0.000 description 2
- 239000007968 orange flavor Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000002601 radiography Methods 0.000 description 2
- 229940061368 sonata Drugs 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 1
- IAJILQKETJEXLJ-KKQCNMDGSA-N (2r,3r,4r,5s)-2,3,4,5-tetrahydroxy-6-oxohexanoic acid Chemical compound O=C[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O IAJILQKETJEXLJ-KKQCNMDGSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- AEMOLEFTQBMNLQ-DTEWXJGMSA-N D-Galacturonic acid Natural products O[C@@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-DTEWXJGMSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-WHZQZERISA-N D-aldose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-WHZQZERISA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010059186 Early satiety Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- WGNIPWQCWPXQFL-UHFFFAOYSA-N [I].[Ba] Chemical compound [I].[Ba] WGNIPWQCWPXQFL-UHFFFAOYSA-N 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 210000001815 ascending colon Anatomy 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 210000003767 ileocecal valve Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 235000010491 tara gum Nutrition 0.000 description 1
- 239000000213 tara gum Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000003144 traumatizing effect Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33207401P | 2001-11-21 | 2001-11-21 | |
| US60/332,074 | 2001-11-21 | ||
| PCT/US2002/037385 WO2003045308A2 (en) | 2001-11-21 | 2002-11-21 | Formulations for use in medical or diagnostic procedures |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2466808A1 CA2466808A1 (en) | 2003-06-05 |
| CA2466808C true CA2466808C (en) | 2009-01-27 |
Family
ID=23296624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002466808A Expired - Lifetime CA2466808C (en) | 2001-11-21 | 2002-11-21 | Formulations for use in medical or diagnostic procedures |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7427391B2 (https=) |
| EP (1) | EP1458328B1 (https=) |
| JP (1) | JP4820054B2 (https=) |
| KR (1) | KR20040071143A (https=) |
| AU (1) | AU2002365395B2 (https=) |
| BR (1) | BR0214314A (https=) |
| CA (1) | CA2466808C (https=) |
| IL (1) | IL162095A0 (https=) |
| RU (1) | RU2004119035A (https=) |
| WO (1) | WO2003045308A2 (https=) |
| ZA (1) | ZA200404023B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7427391B2 (en) * | 2001-11-21 | 2008-09-23 | E-Z-Em, Inc. | Formulations for use in medical and diagnostic procedures |
| US7378081B2 (en) * | 2003-01-29 | 2008-05-27 | Vincon Research Enterprises, Llc | Composition and method for direct visualization of the human appendix |
| US20050180920A1 (en) * | 2003-01-29 | 2005-08-18 | Vincenzo Giuliano | Oral contrast media composition for computerized axial tomographic examinations and method |
| CN100388313C (zh) * | 2003-02-05 | 2008-05-14 | 皇家飞利浦电子股份有限公司 | 定量分析精度指示 |
| US7582283B2 (en) * | 2004-02-13 | 2009-09-01 | Wisconsin Alumni Research Foundation | Contrast agents to improve gastrointestinal tract opacification during abdominal and pelvic CT scans |
| ES2331195T3 (es) | 2004-07-15 | 2009-12-23 | Gynaecologiq B.V. | Composicion y metodo para imagineria medica de cavidades corporales. |
| US9585973B1 (en) * | 2008-06-05 | 2017-03-07 | Peter Quagliano | Palatable liquid dilution vehicles for oral contrast agents |
| NL2003660C2 (en) | 2009-10-16 | 2011-04-19 | Giskit B V | Composition and method for medical imaging of body cavities. |
| WO2011136336A1 (ja) * | 2010-04-30 | 2011-11-03 | 味の素株式会社 | Ｃｔコロノグラフィに用いられる経口投与用液剤及び消化管造影用組成物 |
| AU2019227840B2 (en) * | 2018-02-27 | 2022-12-15 | Trisco ICAP Pty Ltd | An ingredient |
| IT201900003113A1 (it) * | 2019-03-04 | 2020-09-04 | Azienda Ospedaliero Univ Policlinico S Orsola Malpighi Bologna | Bevanda coadiuvante |
| US11730831B2 (en) | 2019-03-26 | 2023-08-22 | Sicreations, Llc | Imaging agents and methods of using the same |
| US11833227B2 (en) | 2019-05-29 | 2023-12-05 | Sicreations, Llc | Methods for preserving a subject and using imaging contrast agents |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB657979A (en) * | 1948-07-03 | 1951-10-03 | Miles Lab | Improvements in or relating to x-ray contrast mediums |
| US3975512A (en) * | 1970-12-21 | 1976-08-17 | University Of Illinois Foundation | Non-toxic brominated perfluorocarbons radiopaque agents |
| US4074709A (en) * | 1976-04-15 | 1978-02-21 | Kaplan Leopold S | Method and device for facilitating double-contrast studies of the upper gastrointestinal tract |
| GB1599881A (en) * | 1977-02-02 | 1981-10-07 | Millington A R | Preparation for diagnostic radiology |
| US4448207A (en) * | 1981-11-03 | 1984-05-15 | Vital Metrics, Inc. | Medical fluid measuring system |
| SE8601563D0 (sv) * | 1986-04-08 | 1986-04-08 | Carbomatrix Ab | Matrismaterial, forfarande for framstellning derav och anvendning derav |
| US5019059A (en) * | 1986-12-15 | 1991-05-28 | Uresil Corporation | Apparatus and method for collecting body fluids |
| US4930997A (en) * | 1987-08-19 | 1990-06-05 | Bennett Alan N | Portable medical suction device |
| AU4492989A (en) * | 1988-10-20 | 1990-05-14 | Fusen H. Chen | Incontinence device |
| US5783171A (en) * | 1989-06-16 | 1998-07-21 | Neorx Corporation | Radionuclide metal N2 S2 chelates substituted with glucose and biotin moieties |
| GB8916782D0 (en) * | 1989-07-21 | 1989-09-06 | Nycomed As | Compositions |
| US4957486A (en) * | 1989-10-02 | 1990-09-18 | Davis Emsley A | Rectal-stomal insert apparatus and method |
| US6088613A (en) | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
| US5368840A (en) * | 1990-04-10 | 1994-11-29 | Imarx Pharmaceutical Corp. | Natural polymers as contrast media for magnetic resonance imaging |
| US5107842A (en) * | 1991-02-22 | 1992-04-28 | Molecular Biosystems, Inc. | Method of ultrasound imaging of the gastrointestinal tract |
| US5179955A (en) | 1991-02-22 | 1993-01-19 | Molecular Biosystems, Inc. | Method of abdominal ultrasound imaging |
| JP3238485B2 (ja) * | 1992-08-07 | 2001-12-17 | 明治乳業株式会社 | 消化管造影用組成物 |
| US5380522A (en) | 1992-08-11 | 1995-01-10 | Day; Charles E. | Method for treatment of irritable bowel syndrome |
| EP0669823A4 (en) * | 1992-10-06 | 1996-03-13 | Molecular Biosystems Inc | Ultrasound imaging of body cavity. |
| JPH06157355A (ja) * | 1992-11-13 | 1994-06-03 | Dai Ichi Seiyaku Co Ltd | Ｍｒｉ用粒状製剤 |
| EP0741581A1 (en) * | 1994-01-28 | 1996-11-13 | Nycomed Imaging As | Oral magnetic particle formulation |
| US5611342A (en) * | 1994-02-15 | 1997-03-18 | Molecular Biosystems, Inc. | Method of computer tomography imaging the gastrointestinal tract and surrounding upper abdominal tissues and organs using an orally administered low density contrast medium |
| US5736121A (en) | 1994-05-23 | 1998-04-07 | Imarx Pharmaceutical Corp. | Stabilized homogenous suspensions as computed tomography contrast agents |
| DE4424233C1 (de) * | 1994-07-09 | 1995-12-07 | Thomas Gieselmann | Orales Echokontrastmittel für Ultraschalldiagnostik |
| US5782762A (en) * | 1994-10-27 | 1998-07-21 | Wake Forest University | Method and system for producing interactive, three-dimensional renderings of selected body organs having hollow lumens to enable simulated movement through the lumen |
| US6066139A (en) * | 1996-05-14 | 2000-05-23 | Sherwood Services Ag | Apparatus and method for sterilization and embolization |
| US5779662A (en) * | 1996-05-20 | 1998-07-14 | Linvatec Corporation | Laparoscopic tissue resection system |
| JP2002511837A (ja) * | 1996-09-10 | 2002-04-16 | メデイノックス，インコーポレイテッド | ポリジチオカルバメート含有マクロ分子と、治療及び診断用途へのその使用 |
| EP0959693A1 (en) * | 1997-01-31 | 1999-12-01 | Fmc Corporation | Texture and stabilizer composition |
| GB9710699D0 (en) * | 1997-05-24 | 1997-07-16 | Danbiosyst Uk | Gastro-retentive controlled release system |
| CN1233505A (zh) * | 1998-04-24 | 1999-11-03 | 胡挽华 | 一种胃肠阴性造影剂及其生产方法 |
| US6214376B1 (en) * | 1998-08-25 | 2001-04-10 | Banner Pharmacaps, Inc. | Non-gelatin substitutes for oral delivery capsules, their composition and process of manufacture |
| JP3099293B2 (ja) * | 1999-02-12 | 2000-10-16 | イトー海外事業株式会社 | 可食印刷用シート及びその製造装置並びに製造方法 |
| JP2001048810A (ja) * | 1999-08-04 | 2001-02-20 | Ina Food Ind Co Ltd | 造影剤用増粘剤 |
| IN192748B (https=) * | 2000-08-29 | 2004-05-15 | Ranbaxy Lab Ltd | |
| IL155204A0 (en) * | 2000-10-02 | 2003-11-23 | Arizeke Pharmaceuticals Inc | Compositions and methods for the transport of biologically active agents across cellular barriers |
| KR20040032918A (ko) | 2001-08-16 | 2004-04-17 | 더 스테이트 오브 오레곤 액팅 바이 앤드 쓰루 더 스테이트 보드 오브 하이어 에쥬케이션 온 비해프 오브 오레곤 스테이트 유니버시티 | 팽창 가능한 위 정지 장치 |
| US7427391B2 (en) * | 2001-11-21 | 2008-09-23 | E-Z-Em, Inc. | Formulations for use in medical and diagnostic procedures |
-
2002
- 2002-11-21 US US10/476,314 patent/US7427391B2/en not_active Expired - Lifetime
- 2002-11-21 RU RU2004119035/15A patent/RU2004119035A/ru not_active Application Discontinuation
- 2002-11-21 AU AU2002365395A patent/AU2002365395B2/en not_active Expired
- 2002-11-21 CA CA002466808A patent/CA2466808C/en not_active Expired - Lifetime
- 2002-11-21 ZA ZA200404023A patent/ZA200404023B/en unknown
- 2002-11-21 WO PCT/US2002/037385 patent/WO2003045308A2/en not_active Ceased
- 2002-11-21 BR BR0214314-3A patent/BR0214314A/pt not_active IP Right Cessation
- 2002-11-21 JP JP2003546813A patent/JP4820054B2/ja not_active Expired - Lifetime
- 2002-11-21 EP EP02804018A patent/EP1458328B1/en not_active Expired - Lifetime
- 2002-11-21 KR KR10-2004-7007813A patent/KR20040071143A/ko not_active Ceased
- 2002-11-21 IL IL16209502A patent/IL162095A0/xx unknown
-
2008
- 2008-09-19 US US12/234,147 patent/US8343462B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002365395B2 (en) | 2006-07-20 |
| EP1458328B1 (en) | 2013-01-30 |
| US7427391B2 (en) | 2008-09-23 |
| KR20040071143A (ko) | 2004-08-11 |
| JP2005510531A (ja) | 2005-04-21 |
| JP4820054B2 (ja) | 2011-11-24 |
| IL162095A0 (en) | 2005-11-20 |
| US20090180963A1 (en) | 2009-07-16 |
| WO2003045308A3 (en) | 2003-12-18 |
| EP1458328A2 (en) | 2004-09-22 |
| EP1458328A4 (en) | 2009-06-17 |
| BR0214314A (pt) | 2004-11-09 |
| RU2004119035A (ru) | 2005-11-20 |
| WO2003045308A2 (en) | 2003-06-05 |
| US20040241093A1 (en) | 2004-12-02 |
| CA2466808A1 (en) | 2003-06-05 |
| US8343462B2 (en) | 2013-01-01 |
| AU2002365395A1 (en) | 2003-06-10 |
| ZA200404023B (en) | 2005-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8343462B2 (en) | Formulations for use in medical and diagnostic procedures | |
| Lauenstein et al. | Optimization of oral contrast agents for MR imaging of the small bowel | |
| US20090136426A1 (en) | Contrast media for using in medical and diagnostic procedures and methods of using the same | |
| JP2005510531A5 (https=) | ||
| WO2022029294A1 (en) | Pet-ct imaging methods, contrast agents and pharmaceutical compositions for use in said imaging methods | |
| Kinner et al. | MRI of the small bowel: can sufficient bowel distension be achieved with small volumes of oral contrast? | |
| Berther et al. | Comparison of neutral oral contrast versus positive oral contrast medium in abdominal multidetector CT | |
| US20260102522A1 (en) | Low x-ray attenuation change hard shelled oral contrast material | |
| Borthne et al. | Osmolarity: a decisive parameter of bowel agents in intestinal magnetic resonance imaging | |
| US7582283B2 (en) | Contrast agents to improve gastrointestinal tract opacification during abdominal and pelvic CT scans | |
| Ajaj et al. | Magnetic resonance colonography without bowel cleansing using oral and rectal stool softeners (fecal cracking)—a feasibility study | |
| Tuñón et al. | Contrast agents for MR enterography | |
| Naik et al. | Evaluation of bowel by computed tomography enterography: comparing the water, mannitol and iodinated oral contrast | |
| Lee et al. | Comparison of static-fluid or excretory magnetic resonance urography with computed tomography urography for visualization of nondilated renal pelvises and ureters in healthy Beagles | |
| Shi et al. | Magnesium sulfate as an oral contrast medium in magnetic resonance imaging of the small intestine | |
| Vikram et al. | Comparison of mannitol and meglumine diatrizoate for stomach and small bowel wall study by computed tomography, a prospective study | |
| Petrocelli et al. | Computed tomography enterography | |
| Oh-oka et al. | Usefulness of MR-seminography using Gd-DTPA in intermediate magnetic field MRI equipment | |
| Marhoon et al. | Role of Multidetector Ct in Characterization of Renal Mass | |
| Lauenstein | MR colonography |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20221121 |